Olipass is developing new RNA medication based on its OliPass PNA (peptide nucleic acid) platform for development of next-gen RNA medication. Its major pipelines consist of clinical trial phase 2a approval for non-opioid arthritis pain medication in Australia, and clinical trial phase 1 approval in the UK.
Investors 3
| Date | Name | Website |
| - | Uno Invest... | unoi.co.kr |
| - | UTC Invest... | utc.co.kr |
| - | KTB Networ... | ktbnetwork... |